FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016804997> ?p ?o ?g. }

• W2016804997 endingPage "805" @default.
• W2016804997 startingPage "799" @default.
• W2016804997 abstract "Between 1987 and 1991, 25 children with advanced rhabdomyosarcoma (20 with IRS Group 3 disease and 5 with Group 4 disease) were entered on a prospective study evaluating selective use of hyperfractionated irradiation (HFI) and reduced-dose conventionally fractionated irradiation (CFI), based on disease status following induction chemotherapy (ifosfamide or melphalan, followed by vincristine, adriamycin, and cyclophosphamide combination) with or without delayed surgery.Patients with gross disease following induction chemotherapy with or without delayed surgery, and whose primary tumor sites did not involve the central nervous system, received HFI (n = 12) at 1.1 Gy twice-a-day to 59.4-63.8 Gy total. Patients with parameningeal primaries and intracranial disease extension received HFI with initiation of therapy (n = 2). Those with microscopic disease following induction chemotherapy with or without delayed surgery (n = 11) received reduced-dose CFI to 40 Gy. Active follow-up ranges from 28-75 months (median = 43 months) with no patient lost to follow-up.Eighteen patients (72%) are alive and without evidence of disease, including 8 of the children with gross residual disease postinduction therapy. The absolute 2-year continuous local tumor control rate is 86% for all patients. Among the 14 who received HFI, the absolute 2-year continuous local tumor control rate is 75% at 33 to 67 months (median = 38 months) postirradiation. Hyperfractionated irradiation was associated with expected enhancement of acute reactions, which all resolved with conservative medical management. Grade 4 or 5 acute toxicities were not seen. Significant late radiation morbidity has, thus far, been minimal and limited to Grade 1 and 2 events. Among the 11 who received reduced-dose CFI, the absolute 2-year continuous local tumor control rate is 100% at 25 to 70 months (median = 40 months) postirradiation.This limited experience suggests that HFI to a dose level of 60 Gy can be used selectively in children with advanced rhabdomyosarcoma left with gross disease following induction chemotherapy, with or without delayed surgery, with an apparent improvement in local control, and minimization of potential late radiation toxicity. Concurrently, those left with microscopic disease following induction therapy can be selectively treated with reduced-dose CFI with excellent local control." @default.
• W2016804997 created "2016-06-24" @default.
• W2016804997 creator A5012516505 @default.
• W2016804997 creator A5032946348 @default.
• W2016804997 creator A5042463331 @default.
• W2016804997 creator A5057242210 @default.
• W2016804997 creator A5066410804 @default.
• W2016804997 creator A5070621756 @default.
• W2016804997 creator A5078153183 @default.
• W2016804997 creator A5082435625 @default.
• W2016804997 creator A5083761980 @default.
• W2016804997 date "1995-02-01" @default.
• W2016804997 modified "2023-09-24" @default.
• W2016804997 title "A phase II trial evaluation selective use of altered radiation dose and fractionation in patients with unresectable rhabdomyosarcoma" @default.
• W2016804997 cites W1861859966 @default.
• W2016804997 cites W1897723143 @default.
• W2016804997 cites W1947572199 @default.
• W2016804997 cites W1967651068 @default.
• W2016804997 cites W1968618193 @default.
• W2016804997 cites W1970473724 @default.
• W2016804997 cites W1971747664 @default.
• W2016804997 cites W1976910795 @default.
• W2016804997 cites W1985006583 @default.
• W2016804997 cites W1989603776 @default.
• W2016804997 cites W1997989704 @default.
• W2016804997 cites W2001938247 @default.
• W2016804997 cites W2016871222 @default.
• W2016804997 cites W2020114585 @default.
• W2016804997 cites W2021640209 @default.
• W2016804997 cites W2045919099 @default.
• W2016804997 cites W2050540541 @default.
• W2016804997 cites W2059609023 @default.
• W2016804997 cites W2076082942 @default.
• W2016804997 cites W2100727105 @default.
• W2016804997 cites W2133555954 @default.
• W2016804997 doi "https://doi.org/10.1016/0360-3016(94)00459-5" @default.
• W2016804997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7860391" @default.
• W2016804997 hasPublicationYear "1995" @default.
• W2016804997 type Work @default.
• W2016804997 sameAs 2016804997 @default.
• W2016804997 citedByCount "11" @default.
• W2016804997 countsByYear W20168049972013 @default.
• W2016804997 crossrefType "journal-article" @default.
• W2016804997 hasAuthorship W2016804997A5012516505 @default.
• W2016804997 hasAuthorship W2016804997A5032946348 @default.
• W2016804997 hasAuthorship W2016804997A5042463331 @default.
• W2016804997 hasAuthorship W2016804997A5057242210 @default.
• W2016804997 hasAuthorship W2016804997A5066410804 @default.
• W2016804997 hasAuthorship W2016804997A5070621756 @default.
• W2016804997 hasAuthorship W2016804997A5078153183 @default.
• W2016804997 hasAuthorship W2016804997A5082435625 @default.
• W2016804997 hasAuthorship W2016804997A5083761980 @default.
• W2016804997 hasConcept C126322002 @default.
• W2016804997 hasConcept C126894567 @default.
• W2016804997 hasConcept C141071460 @default.
• W2016804997 hasConcept C142724271 @default.
• W2016804997 hasConcept C155806632 @default.
• W2016804997 hasConcept C2776611710 @default.
• W2016804997 hasConcept C2776694085 @default.
• W2016804997 hasConcept C2776755627 @default.
• W2016804997 hasConcept C2778256501 @default.
• W2016804997 hasConcept C2778684742 @default.
• W2016804997 hasConcept C2779429289 @default.
• W2016804997 hasConcept C2780844630 @default.
• W2016804997 hasConcept C2908786992 @default.
• W2016804997 hasConcept C509974204 @default.
• W2016804997 hasConcept C71924100 @default.
• W2016804997 hasConceptScore W2016804997C126322002 @default.
• W2016804997 hasConceptScore W2016804997C126894567 @default.
• W2016804997 hasConceptScore W2016804997C141071460 @default.
• W2016804997 hasConceptScore W2016804997C142724271 @default.
• W2016804997 hasConceptScore W2016804997C155806632 @default.
• W2016804997 hasConceptScore W2016804997C2776611710 @default.
• W2016804997 hasConceptScore W2016804997C2776694085 @default.
• W2016804997 hasConceptScore W2016804997C2776755627 @default.
• W2016804997 hasConceptScore W2016804997C2778256501 @default.
• W2016804997 hasConceptScore W2016804997C2778684742 @default.
• W2016804997 hasConceptScore W2016804997C2779429289 @default.
• W2016804997 hasConceptScore W2016804997C2780844630 @default.
• W2016804997 hasConceptScore W2016804997C2908786992 @default.
• W2016804997 hasConceptScore W2016804997C509974204 @default.
• W2016804997 hasConceptScore W2016804997C71924100 @default.
• W2016804997 hasIssue "4" @default.
• W2016804997 hasLocation W20168049971 @default.
• W2016804997 hasLocation W20168049972 @default.
• W2016804997 hasOpenAccess W2016804997 @default.
• W2016804997 hasPrimaryLocation W20168049971 @default.
• W2016804997 hasRelatedWork W1997243509 @default.
• W2016804997 hasRelatedWork W2016804997 @default.
• W2016804997 hasRelatedWork W2057537503 @default.
• W2016804997 hasRelatedWork W2060816095 @default.
• W2016804997 hasRelatedWork W2072765345 @default.
• W2016804997 hasRelatedWork W2116738651 @default.
• W2016804997 hasRelatedWork W2230522317 @default.
• W2016804997 hasRelatedWork W2409817159 @default.
• W2016804997 hasRelatedWork W2412245030 @default.
• W2016804997 hasRelatedWork W4289968232 @default.
• W2016804997 hasVolume "31" @default.

• next